Institute of Cardiovascular and Metabolic Diseases (I2MC - UMR1048)

The new Institute of Cardiovascular and Metabolic Diseases (I2MC) was created in Toulouse on January 1, 2011 by Inserm and Paul Sabatier University.


More than 280 people (scientists, physicians, engineers, technicians, students, postdocs and administrators) are working at I2MC

The research activity focuses on metabolic, cardiovascular and renal diseases. The main feature of I2MC is the gathering of basic scientists together with clinicians working on metabolic risk factors (obesity, diabetes and dyslipidemia) and their cardiovascular complications (thrombosis, atherosclerosis, cardiac and renal failure).

schema accueil v5

I2MC is composed of 14 research teams. The teams share a similar "research philosophy" consisting in multidisciplinary approaches from basic science to clinical trials. In terms of basic research, the laboratories have a large expertise in membrane and intracellular receptors, cell signaling, metabolic pathways, cell/cell interactions and the mechanisms of tissue remodeling. To establish the pathophysiological relevance of the results obtained in basic research, I2MC teams have created original animal models and phenotyping techniques that have gained national recognition and are one of the highlights of the Institute. Translation to the clinic is greatly facilitated by the location within the Rangueil site of Toulouse University Hospitals. Notably, clinical departments devoted to nutrition, cardiovascular and renal diseases, obesity and diabetes are in close vicinity of I2MC. It helps the involvement of a large number of MD-PhD to the scientific activity of the laboratories. More than 25 clinical research protocols coming from original research obtained by I2MC teams have been performed during the last three years.

The industrial valorization of the research is another strength of I2MC. Numerous structured collaborations are ongoing with industrial partners, from SMEs to big pharmas. I2MC research directly contributed to the creation of 4 start up companies.



Latest publications

A non-catalytic function of PI3Kγ drives smooth muscle cell proliferation after arterial damage (team 5)

PMID : 32482794 | Revue : J. Cell. Sci

Auteurs : Lupieri A, Blaise R, Ghigo A, Smirnova N, Sarthou MK, Malet N, Limon I, Vincent P, Hirsch E, Gayr...

Exercise-Released Myokines in the Control of Energy Metabolism (team 4)

PMID : 32116795 | Revue : Front Physiol

Auteurs : Laurens C, Bergouignan A, Moro C

Reappraisal of the optimal fasting time for insulin tolerance tests in mice (team 4)

PMID : 32739449 | Revue : Mol Metab

Auteurs : Carper D, Coué M, Laurens C, Langin D, Moro C

Job offers

  • [CDD] Post-Doctorant

    (team 13)

    3 years position
    "Identify therapeutic target for lymphedema"

  • [CDD] IE

    (team 13)

    2 years postition.
    Gene therapy for lymphedema

  • [Doctorat] Doctorant

    (team 4)

    Lipid droplet hypertrophy: the link between adipocyte dysfunction and cardiometabolic diseases

  • [Doctorat] Doctorant

    (team 1)

    Metabolic function of adipose tissue microvasculature:
    a target of obesity and aging
    Thesis Position in _Endothelium and Metabolism_Toulouse France
    link :